Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.

Kim, Siin Kim, Hyungtae Kim, Eunju Han, Sola Rane, Pratik P Fox, Kathleen M Zhao, Zhongyun Qian, Yi Suh, Hae Sun

REVIEW


07 August 2018

This is a very specific area and the title is misleading by referring to lipid lowering therapies when only statins and/or ezetimibe are investigated. Moreover, ezetimiobe alone has very little effect on lipoproteins and I wonder why other drugs such sas PCSK9 inhibitors were not looked at. I suspect that the research is driven by pharmacological, rather than clinical needs.


RELEVANCE 2
INNOVATIVENESS 3
APPLICABILITY 3
OVERALL 3

PAPER DETAILS


TITLE

Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.

ABSTRACT

PURPOSE
We aimed to study the utilization patterns of lipid-lowering treatment (LLT), including treatment modification, adherence, and possible statin intolerance, in patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes using national claims data in South Korea.

METHODS
A retrospective cohort study was conducted using data from the Korean Health Insurance Review & Assessment Service claims database. Patients aged ≥18 years with >1 outpatient pharmacy claim for a statin and/or ezetimibe dated January 1, 2012, to December 31, 2014, were identified and categorized into the following cohorts: patients with ASCVD, and patients with diabetes mellitus without ASCVD. LLT modification, adherence to index LLT, and possible statin intolerance were explored during the 12 months after the date of first prescription for a statin and/or ezetimibe.

FINDINGS
Among 1,399,872 patients who met the eligibility criteria, 807,547 (57.7%) were patients with ASCVD and 592,325 (42.3%) were patients with diabetes without ASCVD. About half of the patients had no modification in their index treatment (46.2% in the ASCVD cohort and 48.9% in the diabetes cohort), and the most common modification was permanent discontinuation (19.6% in the ASCVD cohort and 21.4% in the diabetes cohort). The mean medication possession ratios were 0.77 in the ASCVD cohort and 0.73 in the diabetes cohort and showed a decreasing trend during the 12-month follow-up period. Among patients who initiated a statin and/or ezetimibe, possible statin intolerance was observed in 53,921 patients (6.7%) in the ASCVD cohort and 42,172 patients (7.1%) in the diabetes cohort.

IMPLICATIONS
In South Korea, a high rate of permanent discontinuation of statin therapy in patients with ASCVD or diabetes places these patients at high risk for cardiovascular events in the future. A decreasing trend of adherence to LLT implies that more intensive education and management are required to improve therapeutic effect and reduce the risk for ASCVD. The high rate of possible statin intolerance highlights an unmet need in the prevention and management of ASCVD in South Korea.



AUTHOR(S)

Kim, Siin Kim, Hyungtae Kim, Eunju Han, Sola Rane, Pratik P Fox, Kathleen M Zhao, Zhongyun Qian, Yi Suh, Hae Sun

JOURNAL

Clinical therapeutics

PLACE

United States